Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Experience of "One Stop TB Diagnostic Solution" Model in Engaging a Private Laboratory for End-to-End Diagnostic Services in the National TB Elimination Program in Hisar, India.
Raju R, Prasad BM, Alavadi U, Saini S, Sabharwal M, Duhan A, Anand S, Lal M, Kaur H, Arora N, Jaju J, Moore M, Ramachandran R, Kumar N, Joshi RP. Raju R, et al. Among authors: ramachandran r. Diagnostics (Basel). 2023 Aug 31;13(17):2823. doi: 10.3390/diagnostics13172823. Diagnostics (Basel). 2023. PMID: 37685361 Free PMC article.
Feasibility of decentralised deployment of Xpert MTB/RIF test at lower level of health system in India.
Raizada N, Sachdeva KS, Sreenivas A, Vadera B, Gupta RS, Parmar M, Kulsange S, Babre A, Thakur R, Gray C, Ramachandran R, Alavadi U, Ghedia M, Vollepore B, Dewan P, Boehme C, Paramsivan CN. Raizada N, et al. Among authors: ramachandran r. PLoS One. 2014 Feb 26;9(2):e89301. doi: 10.1371/journal.pone.0089301. eCollection 2014. PLoS One. 2014. PMID: 24586675 Free PMC article.
Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB.
Raizada N, Sachdeva KS, Nair SA, Kulsange S, Gupta RS, Thakur R, Parmar M, Gray C, Ramachandran R, Vadera B, Ekka S, Dhawan S, Babre A, Ghedia M, Alavadi U, Dewan P, Khetrapal M, Khanna A, Boehme C, Paramsivan CN. Raizada N, et al. Among authors: ramachandran r. PLoS One. 2014 Aug 20;9(8):e105346. doi: 10.1371/journal.pone.0105346. eCollection 2014. PLoS One. 2014. PMID: 25140877 Free PMC article.
Use of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in India.
Sachdeva KS, Raizada N, Sreenivas A, Van't Hoog AH, van den Hof S, Dewan PK, Thakur R, Gupta RS, Kulsange S, Vadera B, Babre A, Gray C, Parmar M, Ghedia M, Ramachandran R, Alavadi U, Arinaminpathy N, Denkinger C, Boehme C, Paramasivan CN. Sachdeva KS, et al. Among authors: ramachandran r. PLoS One. 2015 May 21;10(5):e0126065. doi: 10.1371/journal.pone.0126065. eCollection 2015. PLoS One. 2015. PMID: 25996389 Free PMC article.
Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India.
Moonan PK, Nair SA, Agarwal R, Chadha VK, Dewan PK, Gupta UD, Ho CS, Holtz TH, Kumar AM, Kumar N, Kumar P, Maloney SA, Mase SR, Oeltmann JE, Paramasivan CN, Parmar MM, Rade KK, Ramachandran R, Rao R, Salhorta VS, Sarin R, Sarin S, Sachdeva KS, Selvaraju S, Singla R, Surie D, Tonsing J, Tripathy SP, Khaparde SD. Moonan PK, et al. Among authors: ramachandran r. BMJ Glob Health. 2018 Oct 8;3(5):e001135. doi: 10.1136/bmjgh-2018-001135. eCollection 2018. BMJ Glob Health. 2018. PMID: 30364389 Free PMC article.
Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.
Salhotra VS, Sachdeva KS, Kshirsagar N, Parmar M, Ramachandran R, Padmapriyadarsini C, Patel Y, Mehandru L, Jaju J, Ponnuraja C, Gupta M, Kalaiselvan V, Shamim A, Khaparde S, Swaminathan S; Bedaquiline CAP Site Teams. Salhotra VS, et al. Among authors: ramachandran r. Indian J Tuberc. 2020 Jan;67(1):29-37. doi: 10.1016/j.ijtb.2019.10.002. Epub 2019 Oct 16. Indian J Tuberc. 2020. PMID: 32192613
Strengthened capacity of India´s bedaquiline Conditional Access Programme for introducing new drugs and regimens.
Sachdeva KS, Arora N, Solanki R, Singla R, Sarin R, Bhatnagar A, Khanna A, Atahavale A, Shridhar R, Barua SR, Parmar M, Farooq SI, Ramachandran R, Alavadi U, Swamickan R, Tonsing J, Patel Y, Singla N. Sachdeva KS, et al. Among authors: ramachandran r. Int J Tuberc Lung Dis. 2020 Oct 1;24(10):1067-1072. doi: 10.5588/ijtld.20.0136. Int J Tuberc Lung Dis. 2020. PMID: 33126941
Evolutionary journey of programmatic services and treatment outcomes among drug resistant tuberculosis (DR-TB) patients under National TB Elimination Programme in India (2005-2020).
Sachdeva KS, Parmar M, Patel Y, Gupta R, Rathod S, Chauhan S, Anand S, Ramachandran R. Sachdeva KS, et al. Among authors: ramachandran r. Expert Rev Respir Med. 2021 Jul;15(7):885-898. doi: 10.1080/17476348.2021.1850277. Epub 2021 Jan 21. Expert Rev Respir Med. 2021. PMID: 33307889 Review.
Establishing proof of concept for utility of Trueprep®-extracted DNA in line-probe assay testing.
Rajendran P, Saini S, Kumar N, Vashistha H, Thiruvengadam K, Ramamoorthy T, Gopalaswamy R, Kayesth J, Alavadi U, Moore M, Joshi RP, Ramachandran R, Anand S, Shanmugam S, Padmapriyadarsini C. Rajendran P, et al. Among authors: ramachandran r. Int J Tuberc Lung Dis. 2023 Oct 1;27(10):742-747. doi: 10.5588/ijtld.23.0003. Int J Tuberc Lung Dis. 2023. PMID: 37749831 Free PMC article.
1,330 results